| Detected | Trial | Change |
|---|---|---|
| 2026-07-21 | NCT05927558 Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study |
Trial completed |
| 2026-07-21 | NCT05927558 Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study |
Enrollment reduced: 96 -> 59 participants |
| 2026-07-21 | NCT05927558 Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study |
date change Completion moved earlier: 2026-09 -> 2026-07-15 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04168502 | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | Acute Myeloid Leukemia | Recruiting |
| NCT04184505 | Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | High-risk MDS | Recruiting |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in… | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Active, Not Recruiting |
| Phase 2 | |||
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | Autoimmune Hemolytic Anemia | Recruiting |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | CML, Chronic Phase | Recruiting |
| NCT04475731 | Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | Philadelphia-Positive ALL | Active, Not Recruiting |
| NCT04763928 | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating… | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT06667973 | Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive… | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT06880601 | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple… | Multiple Myleoma | Not Yet Recruiting |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program | T-Lymphocytic Leukemia, Acute | Active, Not Recruiting |
| NCT05306301 | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | Chemotherapy | Active, Not Recruiting |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With… | High Risk CLL | Active, Not Recruiting |
| NCT03610438 | Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic… | Acute Lymphoid Leukemia | Active, Not Recruiting |
| Not specified | |||
| NCT05839392 | Novel Approaches to Target MECOM/EVI1 in AML | AML, Adult | Recruiting |
| NCT05694325 | Biologic Characterization of Patients With ITP | Immune Thrombocytopenia | Recruiting |
| NCT04587856 | Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS… | Myelodysplastic Syndromes | Recruiting |
| NCT04867915 | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06028087 | Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment | Multiple Myeloma | Recruiting |
| NCT06657846 | HRQoL and Financial Toxicity in Patients With VEXAS Syndrome | VEXAS | Recruiting |
| NCT06513273 | Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life… | Acute Myeloid Leukemia | Recruiting |
| NCT06933277 | Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for… | Multiple Myeloma | Recruiting |
| NCT07080970 | Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early… | Acute Myeloid Leukemia | Recruiting |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and… | AML, Adult | Not Yet Recruiting |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | Chronic Lymphocytic Leukemia | Not Yet Recruiting |
| NCT03190525 | Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in… | Multiple Myeloma | Active, Not Recruiting |